Alpine Immune Sciences (NASDAQ:ALPN) Hits New 12-Month High at $64.70

Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Get Free Report) hit a new 52-week high during trading on Monday . The stock traded as high as $64.70 and last traded at $64.70, with a volume of 1290129 shares changing hands. The stock had previously closed at $64.56.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. TD Cowen reiterated a "hold" rating on shares of Alpine Immune Sciences in a report on Tuesday, April 16th. Guggenheim started coverage on shares of Alpine Immune Sciences in a report on Tuesday, April 9th. They issued a "buy" rating and a $55.00 target price for the company. Leerink Partnrs lowered Alpine Immune Sciences from an "outperform" rating to a "market perform" rating in a report on Thursday, April 11th. Morgan Stanley reaffirmed an "equal weight" rating and set a $65.00 price objective (up from $47.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $65.00 target price (up previously from $41.00) on shares of Alpine Immune Sciences in a research note on Thursday, April 11th. Eight research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $50.33.

Alpine Immune Sciences Price Performance

The stock has a market capitalization of $4.24 billion, a PE ratio of -101.09 and a beta of 1.14. The business's fifty day moving average price is $44.23 and its 200-day moving average price is $27.23.

Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report) last announced its quarterly earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The firm had revenue of $30.85 million for the quarter, compared to the consensus estimate of $6.90 million. On average, analysts expect that Alpine Immune Sciences, Inc. will post -1.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alpine Immune Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Alpine Immune Sciences by 87.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 12,630 shares of the biotechnology company's stock worth $501,000 after buying an additional 5,907 shares in the last quarter. Mesirow Financial Investment Management Inc. purchased a new stake in Alpine Immune Sciences in the first quarter valued at approximately $399,000. Raymond James Financial Services Advisors Inc. purchased a new stake in Alpine Immune Sciences in the first quarter valued at approximately $3,033,000. Allspring Global Investments Holdings LLC raised its stake in Alpine Immune Sciences by 331.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 6,414 shares of the biotechnology company's stock valued at $254,000 after purchasing an additional 4,926 shares in the last quarter. Finally, Banque Cantonale Vaudoise purchased a new stake in Alpine Immune Sciences in the first quarter valued at approximately $798,000. 75.17% of the stock is owned by hedge funds and other institutional investors.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.